SS Innovations International (NASDAQ: SSII) announced that its subsidiary, the SS International Centre for Robotics Surgery (SSICRS), has graduated the inaugural class of its Cardiac Robotic Surgery Training program. The five-day course brought together 33 participants from seven countries and 16 international faculty members for classroom instruction, live surgical demonstrations and hands-on training using the company's SSi Mantra surgical robotic system.
The training program is designed to address the growing demand for skilled robotic surgeons worldwide. By combining modern lecture facilities, advanced simulation labs, tele-proctoring and online learning modules, SSICRS aims to support surgeon education and the broader adoption of robotic-assisted surgery. SS Innovations said SSICRS plans to expand its educational offerings through additional condensed training programs covering multiple surgical specialties, including urology, gynecology, thoracic, colorectal, gastrointestinal and general surgery.
The graduation of this first class represents a significant milestone for SS Innovations, which develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery.
SS Innovations is an American company headquartered in India and plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. The success of this training program could accelerate adoption of robotic surgery in emerging markets and reduce barriers to entry for surgeons seeking to learn these techniques.
For more details, the full press release is available at https://ibn.fm/7oFgo. Forward-looking statements in this article involve risks and uncertainties as described in the company's SEC filings. More information is available at http://IBN.fm/Disclaimer.
